Velcade Patent Ruling Puts More Pressure On Ixazomib Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
District court finds formulation patent covering Takeda’s top drug is obvious in light of prior art, opening product up to generic competition in 2017.